Author

J. V. Ravetch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Bioengineering· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Research Focus:host-pathogen & immune response· 5 Organism:human· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

S. Bournazos· 4 shared R. Yamin· 3 shared A. Gazumyan· 2 shared C. M. Rice· 2 shared D. F. Robbiani· 2 shared K. S. Kao· 2 shared M. C. Nussenzweig· 2 shared M. R. MacDonald· 2 shared

Activity by Year

2020-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

S. Bournazos

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer

J. L. Wong, P. Smith, J. Angulo-Lozano, D. Ranti, B. Bochner, J. P. Sfakianos, A. Horowitz, J. V. Ravetch, D. Knorr

This study shows that combining IL-15 with CD40 agonist antibodies improves anti-tumor immunity in bladder cancer by enhancing T cell responses and memory.

bioRxiv · Jan 30, 2023Immunology

Mechanism of glycoform specificity and protection against antibody dependent enhancement by an anti-afucosylated IgG nanobody

A. Gupta, K. S. Kao, R. Yamin, D. A. Oren, Y. Golgur, J. Du, P. Lollar, E. Sundberg, J. V. Ravetch

This paper presents the X-ray structure of a nanobody that binds afucosylated IgG1 Fc and disrupts pathogenic interactions, rescuing mice in a dengue model.

bioRxiv · Jan 23, 2023 · PreprintImmunology

Human FcγRIIIa activation on splenic macrophages drives the in vivo pathogenesis of dengue disease

R. Yamin, K. S. Kao, M. R. MacDonald, T. Cantaert, C. M. Rice, J. V. Ravetch, S. Bournazos

This study shows that anti-DENV IgG antibodies drive dengue pathogenesis via FcγRIIIa on splenic macrophages, leading to inflammation and mortality.

bioRxiv · Nov 2, 2022 · PreprintImmunology

Antibody-lectin chimeras for glyco-immune checkpoint blockade

J. C. Stark, M. A. Gray, S. Wisnovsky, I. Ibarlucea-Benitez, M. Lustig, N. M. Riley, M. K. Ribi, W. J. Errington, B. Bruncsics, C. A. Sarkar, T. Valerius, J. V. Ravetch, C. R. Bertozzi

This paper introduces antibody-lectin chimeras (AbLecs) as a new immunotherapy approach that blocks glyco-immune checkpoints, enhancing cancer immune responses and synergizing with existing checkpoint inhibitors.

bioRxiv · Oct 26, 2022Bioengineering

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

A. Schaefer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, A. Gazumyan, R. S. Baric, D. F. Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, M. C. Nussenzweig, T. P. Sheahan

This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.

bioRxiv · Sep 15, 2020Microbiology

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2

A. Glasgow, J. E. Glasgow, D. Limonta, P. Solomon, I. Lui, Y. Zhang, M. A. Nix, N. J. Rettko, S. A. Lim, S. Zha, R. Yamin, K. Kao, O. S. Rosenberg, J. V. Ravetch, A. P. Wiita, , J. A. Wells

This paper describes engineered ACE2 receptor traps that potently neutralize SARS-CoV-2 by blocking viral entry through enhanced binding affinity.

bioRxiv · Jul 31, 2020Bioengineering

FcRn, but not FcgRs, drives maternal-fetal transplacental transport of human IgGantibodies

S. Borghi, S. Bournazos, N. Thulin, C. Li, A. Gajewski, R. Sherwood, S. Zhang, E. Harris, P. Jagannathan, L.-X. Wang, J. V. Ravetch, T. T. Wang

This study shows that FcRn, not FcγRs, is responsible for maternal-fetal transport of IgG antibodies, suggesting FcRn engineering could improve antibody transfer to the fetus.

bioRxiv · Mar 22, 2020Immunology

A Combination of Two Human Monoclonal Antibodies Limits Fetal Damage by Zika Virus in Macaques

K. K. A. Van Rompay, L. L. Coffey, T. Kapoor, A. Gazumyan, R. I. Keesler, A. Jurado, A. Peace, M. Agudelo, J. Watanabe, J. Usachenko, A. Singapuri, R. Immareddy, A. Ardeshir, J. B. Stuart, S. Bournazos, , D. F. Robbiani

This study shows that two Fc-modified monoclonal antibodies limit fetal neurologic damage and vertical transmission of ZIKV in pregnant macaques.

bioRxiv · Jan 31, 2020Immunology